<!doctype html><html lang=en-us dir=ltr><head><meta charset=utf-8><meta name=viewport content="width=device-width,initial-scale=1"><meta name=description content="The updated version of the EPO Guidelines for Examination is now available (here). The new guidelines come into force on 1 November 2019. The guidelines, as the name suggests, are a guide to the current case law and practise of the EPO and are not legally binding (see IPKat herefor a full discussion of legal precedent at the EPO and the role of the guidelines). The 2019 update to the guidelines incorporates some of the significant developments in the established case law of the Boards of Appeal."><title>2019 updates to the EPO Guidelines for Examination - the highlights</title><link rel=canonical href=https://Nexus-Security.github.io/posts/2016-09-09-2019-updates-to-epo-guidelines-for/><link rel=stylesheet href=/scss/style.min.450926226e724574a6b936335ea06111f8aeb253d932c86cb2cc807341cd2889.css><meta property="og:title" content="2019 updates to the EPO Guidelines for Examination - the highlights"><meta property="og:description" content="The updated version of the EPO Guidelines for Examination is now available (here). The new guidelines come into force on 1 November 2019. The guidelines, as the name suggests, are a guide to the current case law and practise of the EPO and are not legally binding (see IPKat herefor a full discussion of legal precedent at the EPO and the role of the guidelines). The 2019 update to the guidelines incorporates some of the significant developments in the established case law of the Boards of Appeal."><meta property="og:url" content="https://Nexus-Security.github.io/posts/2016-09-09-2019-updates-to-epo-guidelines-for/"><meta property="og:site_name" content="ZYChimne"><meta property="og:type" content="article"><meta property="article:section" content="Posts"><meta property="article:published_time" content="2019-10-13T12:42:00+01:00"><meta property="article:modified_time" content="2019-10-13T12:42:00+01:00"><meta name=twitter:title content="2019 updates to the EPO Guidelines for Examination - the highlights"><meta name=twitter:description content="The updated version of the EPO Guidelines for Examination is now available (here). The new guidelines come into force on 1 November 2019. The guidelines, as the name suggests, are a guide to the current case law and practise of the EPO and are not legally binding (see IPKat herefor a full discussion of legal precedent at the EPO and the role of the guidelines). The 2019 update to the guidelines incorporates some of the significant developments in the established case law of the Boards of Appeal."></head><body class=article-page><script>(function(){const e="StackColorScheme";localStorage.getItem(e)||localStorage.setItem(e,"auto")})()</script><script>(function(){const t="StackColorScheme",e=localStorage.getItem(t),n=window.matchMedia("(prefers-color-scheme: dark)").matches===!0;e=="dark"||e==="auto"&&n?document.documentElement.dataset.scheme="dark":document.documentElement.dataset.scheme="light"})()</script><div class="container main-container flex on-phone--column extended"><aside class="sidebar left-sidebar sticky"><button class="hamburger hamburger--spin" type=button id=toggle-menu aria-label="Toggle Menu">
<span class=hamburger-box><span class=hamburger-inner></span></span></button><header><figure class=site-avatar><a href=/><img src=/img/avatar_hu8b78332b6420dc9affabe23720d11e63_1937019_300x0_resize_q75_box.jpg width=300 height=300 class=site-logo loading=lazy alt=Avatar></a>
<span class=emoji>üçá</span></figure><div class=site-meta><h1 class=site-name><a href=/>ZYChimne</a></h1><h2 class=site-description>Computer Science, Wuhan University</h2></div></header><ol class=social-menu><li><a href=https://github.com/ZYChimne target=_blank title=GitHub><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-brand-github" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z" fill="none"/><path d="M9 19c-4.3 1.4-4.3-2.5-6-3m12 5v-3.5c0-1 .1-1.4-.5-2 2.8-.3 5.5-1.4 5.5-6a4.6 4.6.0 00-1.3-3.2 4.2 4.2.0 00-.1-3.2s-1.1-.3-3.5 1.3a12.3 12.3.0 00-6.2.0C6.5 2.8 5.4 3.1 5.4 3.1a4.2 4.2.0 00-.1 3.2A4.6 4.6.0 004 9.5c0 4.6 2.7 5.7 5.5 6-.6.6-.6 1.2-.5 2V21"/></svg></a></li><li><a href=https://twitter.com/ZChimne target=_blank title=Twitter><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-brand-twitter" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z" fill="none"/><path d="M22 4.01c-1 .49-1.98.689-3 .99-1.121-1.265-2.783-1.335-4.38-.737S11.977 6.323 12 8v1c-3.245.083-6.135-1.395-8-4 0 0-4.182 7.433 4 11-1.872 1.247-3.739 2.088-6 2 3.308 1.803 6.913 2.423 10.034 1.517 3.58-1.04 6.522-3.723 7.651-7.742a13.84 13.84.0 00.497-3.753C20.18 7.773 21.692 5.25 22 4.009z"/></svg></a></li></ol><ol class=menu id=main-menu><li><a href=/><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-home" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><polyline points="5 12 3 12 12 3 21 12 19 12"/><path d="M5 12v7a2 2 0 002 2h10a2 2 0 002-2v-7"/><path d="M9 21v-6a2 2 0 012-2h2a2 2 0 012 2v6"/></svg><span>Home</span></a></li><li><a href=/about-me/><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-user" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><circle cx="12" cy="7" r="4"/><path d="M6 21v-2a4 4 0 014-4h4a4 4 0 014 4v2"/></svg><span>About Me</span></a></li><li><a href=/archives/><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-archive" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><rect x="3" y="4" width="18" height="4" rx="2"/><path d="M5 8v10a2 2 0 002 2h10a2 2 0 002-2V8"/><line x1="10" y1="12" x2="14" y2="12"/></svg><span>Archives</span></a></li><li><a href=/search/><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-search" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><circle cx="10" cy="10" r="7"/><line x1="21" y1="21" x2="15" y2="15"/></svg><span>Search</span></a></li><div class=menu-bottom-section><li id=dark-mode-toggle><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-toggle-left" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><circle cx="8" cy="12" r="2"/><rect x="2" y="6" width="20" height="12" rx="6"/></svg><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-toggle-right" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><circle cx="16" cy="12" r="2"/><rect x="2" y="6" width="20" height="12" rx="6"/></svg><span>Dark Mode</span></li></div></ol></aside><main class="main full-width"><article class=main-article><header class=article-header><div class=article-details><div class=article-title-wrapper><h2 class=article-title><a href=/posts/2016-09-09-2019-updates-to-epo-guidelines-for/>2019 updates to the EPO Guidelines for Examination - the highlights</a></h2></div><footer class=article-time><div><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-calendar-time" width="56" height="56" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><path d="M11.795 21H5a2 2 0 01-2-2V7a2 2 0 012-2h12a2 2 0 012 2v4"/><circle cx="18" cy="18" r="4"/><path d="M15 3v4"/><path d="M7 3v4"/><path d="M3 11h16"/><path d="M18 16.496V18l1 1"/></svg><time class=article-time--published>Oct 13, 2019</time></div><div><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-clock" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><circle cx="12" cy="12" r="9"/><polyline points="12 7 12 12 15 15"/></svg><time class=article-time--reading>6 minute read</time></div></footer></div></header><section class=article-content><p><strong>The updated version of the EPO Guidelines for Examination is now available (<a class=link href=https://www.epo.org/law-practice/legal-texts/html/guidelines2019/e/index.htm target=_blank rel=noopener>here</a>). The new guidelines come into force on 1 November 2019. The guidelines, as the name suggests, are a guide to the current case law and practise of the EPO and are not legally binding (see IPKat <a class=link href="http://ipkitten.blogspot.com/2014/07/what-is-precedent-and-does-epo-have-it.html?_sm_au_=iVVM0WFQNjRDR1RH" target=_blank rel=noopener>here</a>for a full discussion of legal precedent at the EPO and the role of the guidelines). The 2019 update to the guidelines incorporates some of the significant developments in the established case law of the Boards of Appeal.</strong> One key change to the guidelines this year is an update to the assessment of novelty of selection inventions. Other updates include clarification of the definition of ‚Äúsubstance or composition‚Äù and a new section on the criteria of reasonable expectation in an assessment of obviousness for biotechnology inventions.</p><p><strong>A novel selected sub-range is no longer required to be a ‚Äúpurposive selection‚Äù</strong></p><p>In a welcome update, the 2019 guidelines have been updated to reflect the recent Boards of Appeal case law on selection inventions. European patent law considers a selection from the prior art as novel under <a class=link href=https://www.epo.org/law-practice/legal-texts/html/epc/2016/e/ar54.html target=_blank rel=noopener><strong>Article 54EPC</strong></a> if: a) the end points of a claimed sub-range or any point falling within the claimed sub-range are not be disclosed in the prior art and b) the end-points of the claimed range are &ldquo;sufficiently removed&rdquo; from the individual elements disclosed in the prior art. Historically, the EPO also required the selection to be non-arbitrary or ‚Äúpurposive‚Äù. In other words, the selection had to be linked to a technical effect (<strong><a class=link href=https://www.epo.org/law-practice/case-law-appeals/recent/t840198ep1.html target=_blank rel=noopener>T 0198/84</a></strong> (Thiochloroformates) (see r. 7) and <strong><a class=link href=https://www.epo.org/law-practice/case-law-appeals/recent/t890279eu1.html target=_blank rel=noopener>T 0279/89</a></strong> (r. 4.1)).</p><p><a class=link href=https://1.bp.blogspot.com/-2LC4o3rLwjU/XaMMCa7EilI/AAAAAAAAJPQ/_KyHEFi_eMoVskNCkqpB4Fq0O1uNwZthwCNcBGAsYHQ/s1600/Picture2.jpg target=_blank rel=noopener><img src=https://1.bp.blogspot.com/-2LC4o3rLwjU/XaMMCa7EilI/AAAAAAAAJPQ/_KyHEFi_eMoVskNCkqpB4Fq0O1uNwZthwCNcBGAsYHQ/s400/Picture2.jpg loading=lazy></a></p><p><em>Reviewing the case law</em></p><p>However, recent Boards of Appeal decisions have departed from the requirement of a selection to be purposive (e.g. <strong><a class=link href=https://www.epo.org/law-practice/case-law-appeals/recent/t150261eu1.html target=_blank rel=noopener>T 261/15</a></strong>). In <strong><a class=link href=https://www.epo.org/law-practice/case-law-appeals/recent/t051233eu1.html target=_blank rel=noopener>T 1233/05</a></strong>, the Board of Appeal observed that the requirement for a purposive selection of a claimed sub-range &ldquo;appears to fall back upon considerations which should be taken into account in the assessment of inventive step rather than in that of novelty&rdquo; (r. 4.4). The 2019 EPO guidelines have been updated to reflect this position (<strong><a class=link href=https://www.epo.org/law-practice/legal-texts/html/guidelines2019/e/g_vi_8.htm target=_blank rel=noopener>G-VI-8</a></strong>, and <strong><a class=link href=https://www.epo.org/law-practice/legal-texts/html/guidelines2019/e/g_vii_12.htm target=_blank rel=noopener>G-VII-12</a></strong>).</p><p>Notably however, the updated EPO guidelines do not incorporate the recent Boards of Appeal case law on the novelty of purity selection inventions. For many years the EPO considered an increase in the purity of a compound a special case with respect to novelty. The burden of proof was placed on the applicant to show that the claimed level of purity was never achieved in the prior art. However, in a decision last year (<strong><a class=link href=https://www.epo.org/law-practice/case-law-appeals/recent/t131085eu1.html target=_blank rel=noopener>T 1085/13</a></strong>), a Board of Appeal found that previous decision of the Boards were contrary to the principle that novelty can only destroyed by a clear and unambiguous disclosure in the prior art (IPKat post <strong><a class=link href="http://ipkitten.blogspot.com/2019/02/purity-can-be-unconventional-new.html?_sm_au_=iVVM0WFQNjRDR1RH" target=_blank rel=noopener>here</a></strong>). With regards to purity inventions, the 2019 guidelines still only indicate that ‚Äú[a] known compound is not rendered novel merely because it is available with a different degree of purity if the purity can be achieved by conventional means (see T 360/07)‚Äù (G-VI-7).</p><p><strong>How to define a ‚Äúsubstance or composition‚Äù?</strong></p><p>The EPC provides for the patenting of the first or second medical use of a known ‚Äúsubstance or composition‚Äù. The provision is intended to exclude the patenting of the second medical use of a device. However, &ldquo;substance or composition&rdquo; is not defined in the EPC. Determining whether or not something is a substance or composition is not always easy (IPKat: <strong><a class=link href="http://ipkitten.blogspot.com/2018/12/substance-or-device-distinction-without.html?_sm_au_=iVVM0WFQNjRDR1RH" target=_blank rel=noopener>Substance or device - a distinction without a difference?</a></strong>).</p><p>The updated guidelines states that guidance on products which can be seen as &ldquo;substances or compositions&rdquo; can be found in <strong><a class=link href=https://www.epo.org/law-practice/case-law-appeals/recent/t151758eu1.html target=_blank rel=noopener>T 1758/15</a></strong>. The Board in <strong><a class=link href=https://www.epo.org/law-practice/case-law-appeals/recent/t151758eu1.html target=_blank rel=noopener>T 1758/15</a></strong> defined a &ldquo;substance or composition&rdquo; as a product that achieves a direct therapeutic effect by a chemical, as opposed to physical, interaction with the body. However, the current case law does not provide guidance on how a physical versus chemical interaction should be determined, for example with respect to products such as tissue scaffolds.</p><p><strong>‚ÄúReasonable expectation of success‚Äù is not equivalent to ‚Äúa hope to succeed‚Äù</strong></p><p>A whole new section has been added to the guidelines on obviousness in the biotechnology field (<strong><a class=link href=https://www.epo.org/law-practice/legal-texts/html/guidelines2019/e/g_vii_13.htm target=_blank rel=noopener>G-VII-13 Inventive step assessment in the field of biotechnology</a></strong>). The section in particular imports Boards of Appeal case law from <strong><a class=link href=https://www.epo.org/law-practice/case-law-appeals/pdf/t930296ex1.pdf target=_blank rel=noopener>T 296/93</a></strong> on the meaning of ‚Äúreasonable expectation of success‚Äù in the context of an obviousness analysis. The updated guidelines emphasize that a reasonable expectation of success ‚Äúis not to be confused with the ‚Äòhope to succeed‚Äô. If researchers are aware when embarking on their research that, in order to reach a technical solution, they will need not only technical skill but also the ability to make the right non-trivial decisions along the way, this cannot be regarded as a &ldquo;reasonable expectation of success&rdquo;‚Äô (see also <strong><a class=link href=https://www.epo.org/law-practice/legal-texts/html/caselaw/2016/e/clr_i_d_7_1.htm target=_blank rel=noopener>Case Law of the Boards of Appeal, I.D.7.1</a></strong>).</p><p><strong>Novelty of a product claim with process features</strong></p><p>A new section confirms that a claim may contain both product and process features (<strong><a class=link href=https://www.epo.org/law-practice/legal-texts/html/guidelines2019/e/f_iv_4_12_1.htm target=_blank rel=noopener>F-IV-4.12.1 Product claim with process features</a></strong>). The guidelines also clarify that the same criteria of novelty should be applied to such claims as are applied to product-by-process claims. Particularly, the process features of a product claim with process features are only novel if the product produced by the process is novel [Merpel: is this sentence in contention for the patent tongue-twister of the year?].</p><p><strong>The hot chilli pepper of ‚Äúessentially biological processes‚Äù</strong></p><p>The European patent community is eagerly awaiting the response of the Enlarged Board of Appeal (EBA) to the EPO president‚Äôs referral in <strong><a class=link href=http://documents.epo.org/projects/babylon/eponet.nsf/0/4F62ECCAF1B2F2F5C12584020026796E/$File/Referral%20under%20Art.%20112%281%29%28b%29%20EPC-%20G%203-19.pdf target=_blank rel=noopener>G 3/19</a></strong> (Pepper) (IPKat post: <strong><a class=link href="http://ipkitten.blogspot.com/2019/04/pepper-gets-spicy-epo-presidents.html?_sm_au_=iVVM0WFQNjRDR1RH" target=_blank rel=noopener>Pepper gets spicy: The EPO President&rsquo;s Referral to the EBA</a></strong>). The nub of the issue is whether the Administrative Council‚Äôs amendment of <strong><a class=link href=https://www.epo.org/law-practice/legal-texts/html/epc/2016/e/r28.html target=_blank rel=noopener>Rule 28(2) EPC</a></strong> (excluding products produced by essentially biological processes from patentability) was lawful given the contradiction of the new Rule with the interpretation of <strong><a class=link href=https://www.epo.org/law-practice/legal-texts/html/epc/2016/e/ar53.html target=_blank rel=noopener>Article 53(b) EPC</a></strong> by the EBA in <strong><a class=link href=https://www.epo.org/law-practice/case-law-appeals/recent/g120002ex1.html target=_blank rel=noopener>G 2/12</a></strong> (Broccoli/Tomato II). Whilst the President‚Äôs referral is pending, the guidance that <strong><a class=link href=https://www.epo.org/law-practice/legal-texts/html/epc/2016/e/r28.html target=_blank rel=noopener>Rule 28(2) EPC</a></strong> excludes products produced by essentially biological processes from patentability remains unchanged in the 2019 guidelines (G-II.5.4). However, as of 4 April 2019, all proceedings before the EPO potentially impacted by the outcome of the referral have been stayed _ex officio_until the EBA‚Äôs decision on the referral (<strong><a class=link href=https://www.epo.org/law-practice/legal-texts/official-journal/information-epo/archive/20190410.html target=_blank rel=noopener>EPO Notice</a></strong>).</p><p>In a minor update, the guidelines on this topic have been updated to explicitly specify that selfing (i.e. self-fertilization) of a transgenic plant should be considered an ‚Äúessentially biological process‚Äù.</p><p><strong>The exclusion of computer programs from patentability</strong></p><p>The patentability of software is another hot topic at the moment, and subject to its own referral to the EBA (IPKat: <strong><a class=link href="http://ipkitten.blogspot.com/2019/03/the-patentability-of-computer-simulated.html?_sm_au_=iVVM0WFQNjRDR1RH" target=_blank rel=noopener>The patentability of computer simulated methods - another referral to the Enlarged Board of Appeal</a></strong>). The 2019 guidelines include some updates to the section relating the patentability of artificial intelligence and machine learning. In particular, the guidelines now clarify that ‚Äú[t]erms such as ‚Äòsupport vector machine‚Äô, ‚Äòreasoning engine‚Äô or ‚Äòneural network‚Äô may, depending on the context, merely refer to abstract models or algorithms and thus do not, on their own, necessarily imply the use of a technical means. This has to be taken into account when examining whether the claimed subject-matter has a technical character as a whole (Art. 52(1), (2) and (3))‚Äù.</p><p><strong>Final note and question</strong></p><p>Attentive readers may have noticed that many of the updates this year are in the form of citations of Boards of Appeal decisions. Case law references from the Boards have in the past been confined to the Case Law of the Boards of Appeal. The Guidelines have previously mostly refrained from referencing Boards of Appeal decisions on which the guidance was based. Why the change? Do readers have any insights?</p></section><footer class=article-footer><section class=article-copyright><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-copyright" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><circle cx="12" cy="12" r="9"/><path d="M14.5 9a3.5 4 0 100 6"/></svg><span>Licensed under CC BY-NC-SA 4.0</span></section></footer></article><footer class=site-footer><section class=copyright>&copy;
2020 -
2022 ZYChimne</section><section class=powerby>Built with <a href=https://gohugo.io/ target=_blank rel=noopener>Hugo</a><br>Theme <b><a href=https://github.com/CaiJimmy/hugo-theme-stack target=_blank rel=noopener data-version=3.11.0>Stack</a></b> designed by <a href=https://jimmycai.com target=_blank rel=noopener>Jimmy</a></section></footer><div class=pswp tabindex=-1 role=dialog aria-hidden=true><div class=pswp__bg></div><div class=pswp__scroll-wrap><div class=pswp__container><div class=pswp__item></div><div class=pswp__item></div><div class=pswp__item></div></div><div class="pswp__ui pswp__ui--hidden"><div class=pswp__top-bar><div class=pswp__counter></div><button class="pswp__button pswp__button--close" title="Close (Esc)"></button>
<button class="pswp__button pswp__button--share" title=Share></button>
<button class="pswp__button pswp__button--fs" title="Toggle fullscreen"></button>
<button class="pswp__button pswp__button--zoom" title="Zoom in/out"></button><div class=pswp__preloader><div class=pswp__preloader__icn><div class=pswp__preloader__cut><div class=pswp__preloader__donut></div></div></div></div></div><div class="pswp__share-modal pswp__share-modal--hidden pswp__single-tap"><div class=pswp__share-tooltip></div></div><button class="pswp__button pswp__button--arrow--left" title="Previous (arrow left)"></button>
<button class="pswp__button pswp__button--arrow--right" title="Next (arrow right)"></button><div class=pswp__caption><div class=pswp__caption__center></div></div></div></div></div><script src=https://cdn.jsdelivr.net/npm/photoswipe@4.1.3/dist/photoswipe.min.js integrity="sha256-ePwmChbbvXbsO02lbM3HoHbSHTHFAeChekF1xKJdleo=" crossorigin=anonymous defer></script><script src=https://cdn.jsdelivr.net/npm/photoswipe@4.1.3/dist/photoswipe-ui-default.min.js integrity="sha256-UKkzOn/w1mBxRmLLGrSeyB4e1xbrp4xylgAWb3M42pU=" crossorigin=anonymous defer></script><link rel=stylesheet href=https://cdn.jsdelivr.net/npm/photoswipe@4.1.3/dist/default-skin/default-skin.css integrity="sha256-c0uckgykQ9v5k+IqViZOZKc47Jn7KQil4/MP3ySA3F8=" crossorigin=anonymous><link rel=stylesheet href=https://cdn.jsdelivr.net/npm/photoswipe@4.1.3/dist/photoswipe.css integrity="sha256-SBLU4vv6CA6lHsZ1XyTdhyjJxCjPif/TRkjnsyGAGnE=" crossorigin=anonymous></main></div><script src=https://cdn.jsdelivr.net/npm/node-vibrant@3.1.5/dist/vibrant.min.js integrity="sha256-5NovOZc4iwiAWTYIFiIM7DxKUXKWvpVEuMEPLzcm5/g=" crossorigin=anonymous></script><script type=text/javascript src=/ts/main.js defer></script>
<script>(function(){const e=document.createElement("link");e.href="https://fonts.googleapis.com/css2?family=Lato:wght@300;400;700&display=swap",e.type="text/css",e.rel="stylesheet",document.head.appendChild(e)})()</script></body></html>